ETHNOPHARMACOLOGY: The main components of HuangKui capsules' are the total flavonoids extracted from the flowers of Abelmoschus manihot L medic. They have been widely used to treat chronic glomerulonephritis, diabetic nephropathy and nephrotic syndrome. The combination of HuangKui capsules and glibenclamide is a possible therapy for patients with diabetes mellitus and diabetic nephropathy. However, there is no report about effects of HuangKui capsules on the glibenclamide pharmacokinetics till now. AIM OF THE STUDY: This study was aimed investigating the effect of HuangKui capsules on pharmacokinetics of glibenclamide in rats. MATERIAL AND METHODS: Eight rats were administered with an oral dose of HuangKui capsules (0.75gkg(-1)) once daily for 10 consecutive days. All the rats were administered orally with the glibenclamide (1mgkg(-1)) before the first time and after the last time given HuangKui capsules. LC-MS/MS was utilized to determine the concentration of glibenclamide in rat plasma and to calculate the corresponding pharmacokinetic parameters. The statistical differences of the two cycles were evaluated by paired-samples t-test. RESULTS: In the rats treated with HuangKui capsules and glibenclamide, the t(1/2), the time point of maximum plasma concentration (T(max)) of glibenclamide increased obviously (p<0.05) compared with the glibenclamide alone, while maximum plasma concentrations (C(max)), area under the plasma concentration-time curve (AUC((0-t))) decreased significantly (p<0.05). There was no significant difference between other parameters. CONCLUSION: HuangKui capsules can reduce the absorption of glibenclamide and accelerate the metabolism of glibenclamide.
ETHNOPHARMACOLOGY: The main components of HuangKui capsules' are the total flavonoids extracted from the flowers of Abelmoschus manihot L medic. They have been widely used to treat chronic glomerulonephritis, diabetic nephropathy and nephrotic syndrome. The combination of HuangKui capsules and glibenclamide is a possible therapy for patients with diabetes mellitus and diabetic nephropathy. However, there is no report about effects of HuangKui capsules on the glibenclamide pharmacokinetics till now. AIM OF THE STUDY: This study was aimed investigating the effect of HuangKui capsules on pharmacokinetics of glibenclamide in rats. MATERIAL AND METHODS: Eight rats were administered with an oral dose of HuangKui capsules (0.75gkg(-1)) once daily for 10 consecutive days. All the rats were administered orally with the glibenclamide (1mgkg(-1)) before the first time and after the last time given HuangKui capsules. LC-MS/MS was utilized to determine the concentration of glibenclamide in rat plasma and to calculate the corresponding pharmacokinetic parameters. The statistical differences of the two cycles were evaluated by paired-samples t-test. RESULTS: In the rats treated with HuangKui capsules and glibenclamide, the t(1/2), the time point of maximum plasma concentration (T(max)) of glibenclamide increased obviously (p<0.05) compared with the glibenclamide alone, while maximum plasma concentrations (C(max)), area under the plasma concentration-time curve (AUC((0-t))) decreased significantly (p<0.05). There was no significant difference between other parameters. CONCLUSION: HuangKui capsules can reduce the absorption of glibenclamide and accelerate the metabolism of glibenclamide.